Objective
Monoclonal antibodies (mAbs) represent a new form of protein-based drug having demonstrated a significant impact on the treatment of several types of cancers.
Their specificity towards cell surface receptors makes them able to target and destroy tumour cells. However, a lot of progress is still necessary to understand the mechanism of binding and activity of antibodies in order to improve their targeting capabilities and their efficiency.
To reach these objectives, the BMC project proposes to:
- Develop a recombinant bispecific mAb with tetrameric binding sites, directed against two different antigens expressed on the same target tumour cell;
- Develop new bispecific or bifunctional molecules with the property of crosslinking two different receptors on the surface of the cell;
- Modify the carbohydrate moiety of bispecific antibodies and the tumour targeting of the complement regulator molecule, properdin, to trigger the activation of the complement enzymatic cascade at the tumour site.
The recombinant molecules are directed against a selected target antigen for mAb therapy, CDS, as well as a B-cell marker to be selected, in order to treat a specific type of leukaemia, the B-CLL. However, the described innovative cancer immunotherapy strategy will also be extended to the treatment of many other types of cancers especially all carcinomas.
The partnership gathers 9 partners recovering the needs of the BMC project:
- 7 RTDs specialized in genetic engineering (CNRS), innovative molecules design (UNIL), antibodies vectorisation with nanoparticles (HUJI), CDC activity improvement and cell lines and animal models development (GIENSAT), mechanisms of therapeutic antibodies on patients' cells (OORRBG), toxicology studies and standardization (ITEM);
- 2 biotechnology SMEs specialized in therapeutic antibodies development (MAT) and antibodies in-vitro production (MABGENE);
- A company dedicated to the project management until month 50: ALMA.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering
- natural sciences biological sciences biochemistry biomolecules carbohydrates
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine oncology leukemia
- medical and health sciences basic medicine toxicology
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
MÜNCHEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.